Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 2.05
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is 'cheap' on EV/EBITDA, overvalued on P/FC.
Data is available to registered users only
Buy
Sell